Etoposide

Generic name
Etoposide
Brand name
ATC Code
L01CB01
Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Oncological conditions
  • Route of administration not applicable
    • 0 years up to 18 years

      • The dose and dosing frequency of cytostatic agents depend on the condition and are very much subject to new insights. Cytostatic drugs are mostly used in oncology and haematology in combinations. For this reason, please refer to the detailed treatment protocols; it is also the reason why no dose recommendations have been included

        The following indicative dosages have been stated by the manufacturer:  
        75-150 mg/m²/day for 2-5 days.

Renal impaiment in children > 3 months

At a creatinine clearance of > 50 ml/min/1.73m²:
Dose adjustment is not required
At a creatinine clearance of 10-50 ml/min
Reduce the initial dose to 75% of the standard dose, then dose depending on clinical effect and tolerance by the patient
At a creatinine clearance of less than 10 ml/min:
no generalized recommendations are given

Information
The clearance of etoposide is less when the renal function is reduced. The risk of side effects is elevated as a result.

Clinical consequences:
The key dose-related side effects are bone marrow depression (above all leukopenia), gastrointestinal problem and stomatitis.

 

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Extravasation:Severe reactions are not to be expected.

Check the infusion for precipitates.

General cytostatic: a range of cytostatics can trigger hypersensitivity reactions. An emergency set (containing epinephrine, clemastine and hydrocortisone) should be present in the treatment room. The emergency set also contains specific antidotes.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Vinca alkaloids and analogues
L01CA01
L01CA02

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Pharmachemie B.V., SmPC Toposin (RVG 16010) dd 04-10-2017, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring


Overdose